{
  "id": "amyloid",
  "title": "Amyloid",
  "lang": "en",
  "source_lang": "en",
  "summary": "Amyloid is an ordered fibrillar protein assembly defined by cross-beta structure, associated with diverse diseases and with normal biological functions.",
  "category": "science",
  "subcategory": "biology",
  "type": "concept",
  "aliases": [],
  "generated_at": "2026-11-03",
  "model": "pro/gpt-6.1-sol",
  "url": "https://aiwiki.page/en/amyloid/",
  "translations": {
    "zh-Hans": {
      "url": "https://aiwiki.page/zh/amyloid/",
      "json": "https://aiwiki.page/zh/amyloid.json"
    }
  },
  "sections": [
    {
      "heading": "",
      "text": "Amyloid is a highly ordered assembly of proteins or protein fragments in which repeating molecular units form elongated fibrils with a characteristic cross-beta architecture. The term does not identify a single substance: proteins with unrelated sequences and normal functions can adopt an amyloid state. Some amyloids accumulate in tissues and contribute to disease, whereas others perform regulated biological functions, including the construction of microbial extracellular structures and the organization of specialized cellular compartments.\n\nAmyloid is important because it connects molecular structure with processes operating at very different scales, from the conversion of individual protein molecules to organ dysfunction and the inheritance of biological information. Its study brings together protein folding, physical chemistry, structural biology, pathology, and materials science. A central distinction is between amyloid as a structural state, amyloidosis as a group of diseases involving tissue deposition, and particular amyloid-forming molecules such as amyloid-beta. These terms are related but are not interchangeable."
    },
    {
      "heading": "Definition and historical development",
      "text": "The name amyloid derives from a word meaning “starch-like.” In 1854, Rudolf Virchow applied the term to abnormal material whose staining reactions suggested a relationship to starch or related carbohydrates. Chemical investigations subsequently established that the characteristic deposits were predominantly proteinaceous. The historical name survived this correction and now refers to a distinctive form of protein organization rather than a carbohydrate composition.\n\nFor much of the twentieth century, amyloid was defined chiefly through tissue pathology. Deposits appeared relatively homogeneous under conventional light microscopy, bound the dye Congo red, and displayed characteristic birefringence when examined with polarized light. Electron microscopy revealed that this apparently amorphous material contained fine, generally unbranched fibrils. The customary description of “apple-green birefringence” remains widely used, although the observed colors depend on specimen orientation, optical conditions, and staining technique; they are not invariably a uniform green.\n\nA major structural advance came in 1968, when X-ray studies by E. D. Eanes and G. G. Glenner demonstrated the cross-beta diffraction pattern of amyloid fibrils. These findings established that deposits from different diseases shared an underlying molecular organization. Subsequent work identified their constituent proteins and showed that systemic amyloidosis was not one chemically uniform disease. Immunoglobulin light chains, serum amyloid A-derived fragments, and transthyretin, for example, can each form deposits with broadly similar microscopic appearances but very different biological origins.\n\nThe word now has overlapping pathological and biophysical uses. In clinical pathology, amyloid generally denotes tissue deposits with characteristic staining and fibrillar properties. In molecular research, assemblies may be described as amyloid when their cross-beta structure is established, even if they were produced in a laboratory and have never occurred in diseased tissue. Some intracellular protein filaments share amyloid architecture without matching every historical criterion developed for extracellular deposits. Conversely, not every insoluble protein aggregate is amyloid: disordered precipitates, inclusion bodies, and other filaments can have different structures.\n\nDisease-associated amyloid proteins are conventionally designated with an initial “A,” followed by an abbreviation identifying the precursor or fibril protein. Thus AL refers to immunoglobulin light-chain amyloid, AA to serum amyloid A-derived amyloid, and ATTR to transthyretin amyloid. This nomenclature emphasizes the molecular identity of the deposit rather than its appearance or anatomical location, a distinction essential to interpreting its cause."
    },
    {
      "heading": "Molecular architecture and structural diversity",
      "text": "The defining cross-beta arrangement consists of beta strands oriented approximately perpendicular to the fibril axis, with beta sheets extending along that axis. Neighboring strands are stabilized by repeated backbone hydrogen bonds. Their axial separation is typically about \\(0.47\\ \\mathrm{nm}\\), producing a characteristic diffraction reflection. A second, more variable spacing, often around \\(1\\ \\mathrm{nm}\\), reflects separation between beta sheets. These dimensions describe recurrent structural relationships, not a complete molecular blueprint shared by every fibril.\n\nAmyloid fibrils commonly measure several nanometres to a few tens of nanometres across and can extend for micrometres. Many contain two or more associated protofilaments, although single-protofilament forms also occur. Twisting of the protofilaments produces periodic variations in apparent width in electron micrographs. The ordered core may contain only part of the precursor protein; flexible terminal regions and loops can remain outside it. Proteolytic cleavage before or after assembly can further alter which segments are retained in a tissue deposit.\n\nSome amyloid-forming peptide segments create a “steric zipper,” in which side chains from opposing beta sheets interdigitate across a closely packed interface. This concept emerged from atomic structures of short peptides and explains one important mode of stabilization. Full-length disease-associated fibrils, however, frequently contain more elaborate folds, including curved sheets, beta arches, cavities, and multiple interfaces. Their stability reflects backbone bonding, side-chain packing, electrostatic interactions, and the hydrophobic effect, rather than one universal packing arrangement.\n\nA single protein sequence can form several distinct fibril structures, a phenomenon called structural polymorphism. Different polymorphs may vary in the conformation of each protein subunit, the number of protofilaments, or the interface between them. Conversely, different proteins can converge on similar overall fibrillar shapes. Consequently, fibril appearance alone is insufficient to determine either protein identity or atomic structure. Sequence variants, chemical modifications, solution conditions, and associated molecules can favor particular folds.\n\nAdvances in cryo-electron microscopy have made it possible to determine near-atomic structures of many fibrils extracted directly from human tissue. Such studies have shown that laboratory-grown assemblies do not necessarily reproduce the structures found in disease. They have also revealed characteristic tau filament folds associated with different neuropathological conditions. Molecular identity and molecular conformation therefore provide complementary information: identifying the protein answers what the fibril contains, whereas resolving its fold reveals how that protein is organized."
    },
    {
      "heading": "Nucleation, growth, and cellular quality control",
      "text": "Amyloid formation generally involves a kinetic barrier. Although an assembled state may be stable under particular conditions, isolated protein molecules do not necessarily enter it rapidly. They must first generate a sufficiently organized nucleus that can support further growth. This process, called protein aggregation, can involve partial unfolding of a normally folded protein or rearrangement of a protein that is intrinsically disordered. Exposure of normally buried aggregation-prone segments can be more important than wholesale loss of structure.\n\nIn a simplified description, primary nucleation forms a new growth-competent assembly from soluble molecules, and elongation adds molecules to existing fibril ends. Other processes can greatly accelerate accumulation. Fragmentation breaks a fibril into pieces, increasing the number of ends available for elongation. Secondary nucleation generates new nuclei on the surface of pre-existing aggregates. These mechanisms can produce positive feedback: the accumulated material increases the rate at which additional material forms. Their relative importance varies with the protein and experimental environment.\n\nMany laboratory measurements show a sigmoidal increase in aggregate mass, with a lag phase, a rapid-growth phase, and a plateau. The lag phase is not necessarily an interval without aggregation; small populations of nuclei or other intermediates may already be present. Adding preformed fibrils, or “seeds,” can shorten the lag by bypassing part of the nucleation barrier. Nevertheless, similar-looking growth curves can arise from different mechanisms. Establishing a mechanism requires measurements across concentrations and conditions, rather than interpreting a single curve.\n\nFactors influencing assembly include protein concentration, pH, ionic composition, temperature, agitation, membrane surfaces, and chemical modification. A mutation may destabilize a precursor’s normal fold, change its cleavage, increase its production, or directly improve packing within a fibril. Surfaces can locally concentrate proteins or orient them for assembly. Lipids and other molecules may either promote or inhibit aggregation, depending on the system; their effects cannot be predicted simply from whether they bind the protein.\n\nCells oppose inappropriate aggregation through protein quality-control systems, collectively termed proteostasis. Molecular chaperones assist folding or bind exposed hydrophobic regions, while proteolytic systems remove damaged proteins. The ubiquitin–proteasome system degrades many soluble substrates, and lysosomal pathways, including autophagy, participate in clearing larger structures and damaged cellular components. These defenses are compartment-specific and have finite capacities. Aging, increased precursor production, destabilizing mutations, or impaired clearance can shift the balance toward persistence of aggregation-prone species without making aggregation an inevitable consequence of any one factor."
    },
    {
      "heading": "Systemic and localized amyloidoses",
      "text": "Amyloidosis comprises diseases in which amyloid deposition contributes to tissue dysfunction. In systemic forms, a circulating precursor supplies deposits in multiple organs; in localized forms, precursor production and deposition are more restricted. Anatomical distribution is highly variable. The kidneys, heart, liver, peripheral nerves, gastrointestinal tract, and soft tissues are affected in different combinations, and the organ pattern cannot by itself establish the molecular type.\n\nAL amyloidosis arises from monoclonal immunoglobulin light chains produced by an abnormal population of plasma cells or, less commonly, another B-cell lineage disorder. Particular light-chain sequences and structural properties influence their tendency to misfold and aggregate. The condition may involve the kidneys, heart, nerves, and other tissues, but it is not synonymous with multiple myeloma. Detecting a monoclonal immunoglobulin also does not prove that a tissue deposit is AL: monoclonal gammopathy can coexist with a different amyloid disease, particularly in older populations.\n\nAA amyloidosis develops from serum amyloid A, an acute-phase protein whose circulating concentration can rise markedly during sustained inflammation. Persistent inflammatory diseases and certain chronic infections can provide a prolonged supply of precursor. The deposited fibril protein consists largely of fragments derived from serum amyloid A. Kidney involvement is particularly important, often manifesting as substantial urinary protein loss and declining renal function. The disease illustrates how a normal component of the inflammatory response can become a pathogenic precursor when its production remains persistently elevated.\n\nTransthyretin is a circulating protein that normally forms a tetramer and participates in transport of thyroxine and retinol-binding protein. Dissociation of the tetramer permits subsequent misfolding and aggregation. ATTR amyloidosis can arise from pathogenic variants in the TTR gene or from the wild-type protein. Variant-associated disease has diverse cardiac and neurological presentations, while wild-type ATTR commonly manifests as cardiomyopathy in older adults. These categories describe the precursor sequence, not two wholly separate aggregation mechanisms.\n\nOther forms reveal the variety of routes to deposition. Beta-2-microglobulin amyloid can accumulate in people receiving long-term dialysis, with prominent osteoarticular involvement. Certain hereditary amyloidoses involve fibrinogen A alpha-chain, apolipoproteins, gelsolin, or lysozyme. Localized deposits may derive from calcitonin in medullary thyroid carcinoma, islet amyloid polypeptide in pancreatic islets, or insulin at repeated injection sites. Tissue damage can result from disruption of architecture, altered mechanical properties, vascular involvement, and biochemical toxicity. The amount of visible deposit alone does not fully predict functional impairment."
    },
    {
      "heading": "Amyloid in neurodegeneration and prion biology",
      "text": "Amyloid-beta is a family of peptides generated by sequential cleavage of amyloid precursor protein. Cleavage involving beta-secretase and gamma-secretase produces peptides of different lengths; forms ending at residues 40 and 42 are especially well studied. Amyloid-beta 42 has a greater tendency to aggregate under many experimental conditions. In Alzheimer disease, extracellular amyloid-beta plaques occur alongside intracellular tau pathology, synaptic changes, neuronal loss, and inflammatory responses. Amyloid-beta can also accumulate in cerebral blood-vessel walls, producing cerebral amyloid angiopathy.\n\nGenetic evidence strongly connects altered amyloid-beta production or processing with some inherited forms of Alzheimer disease. Pathogenic variants in the amyloid precursor protein gene and in the presenilin genes can cause autosomal dominant disease, and increased dosage of the precursor gene is relevant to amyloid pathology in Down syndrome. These observations establish an important role for the pathway but do not make plaque abundance a direct measure of clinical impairment. Amyloid pathology can precede symptoms by years, and cognition is also influenced by tau pathology, vascular injury, and other processes.\n\nTau and alpha-synuclein provide other prominent examples of proteins forming amyloid-like intracellular filaments in neurodegenerative disorders. Tau normally interacts with microtubules; its pathological assemblies occur in Alzheimer disease and several other tauopathies. Alpha-synuclein is a presynaptic protein and a major constituent of Lewy bodies and related inclusions. Disease-associated fibrils from these proteins can have different conformations in different disorders, linking structural polymorphism to neuropathological classification.\n\nThe identity of the most damaging assembly remains a major research question. Small soluble aggregates, often called oligomers, can disrupt membranes, alter synaptic function, interfere with protein handling, or activate inflammatory pathways in experimental systems. Mature fibrils and deposits can also affect tissue directly or provide surfaces for generating additional assemblies. “Oligomer,” however, describes a range of sizes and structures rather than one chemically uniform toxin. Results obtained with one preparation cannot automatically be generalized to every aggregate of the same protein.\n\nPrions are a special case in which a protein conformation can propagate and, under appropriate circumstances, transmit disease between hosts. Stanley Prusiner introduced the term in 1982. Mammalian prion diseases involve abnormal conformations of the prion protein, although not every infectious prion assembly forms a classic amyloid plaque. Other neurodegeneration-associated proteins can exhibit seeded propagation in cells or experimental animals, but such behavior does not by itself establish ordinary person-to-person contagiousness. Molecular templating, spread within an organism, and epidemiological transmissibility are distinct properties."
    },
    {
      "heading": "Functional amyloids in living systems",
      "text": "Amyloid architecture is not intrinsically pathological. Some organisms use it to construct durable extracellular structures, organize biochemical processes, or store biological information. Such assemblies are called functional amyloids. Their usefulness derives partly from the same properties that complicate disease-associated deposition: cooperative assembly, resistance to degradation, mechanical strength, and the ability to form extended structures from many repeated subunits. Biological regulation determines where, when, and how these properties are employed.\n\nThe curli fibers of certain bacteria, including Escherichia coli and Salmonella, are among the best-characterized examples. Curli contribute to surface attachment and the architecture of a biofilm. Their major subunit, CsgA, is exported before assembling into extracellular fibers, while CsgB helps nucleate assembly at the cell surface. Additional components control secretion and limit inappropriate intracellular aggregation. The system therefore separates precursor synthesis from fibril formation and localizes assembly to a biologically useful site.\n\nFilamentous Streptomyces bacteria produce chaplin proteins that help aerial structures emerge from a moist environment. These proteins contribute to hydrophobic surface layers and can form amyloid assemblies. Fungi provide different examples. The HET-s protein of Podospora anserina adopts a prion state involved in a genetically specified incompatibility system. Yeast prions such as those based on Sup35 or Ure2 demonstrate that an inherited phenotype can depend on a self-propagating protein conformation rather than a change in DNA sequence. Such phenotypes can be beneficial, neutral, or detrimental depending on conditions.\n\nIn mammals, the best-established example is PMEL, a protein that forms fibrillar scaffolds within melanosomes. These specialized organelles support melanin synthesis, and the PMEL matrix helps organize pigment deposition. Proteolytic processing, acidic compartmental conditions, and intracellular trafficking constrain the assembly process. This example is particularly informative because it shows that a cell can deliberately generate an amyloid-like material while limiting exposure of the rest of the cell to potentially troublesome intermediates.\n\nClaims of physiological amyloid require more than showing that a protein can aggregate in a test tube. Evidence must connect the assembly to its natural setting, establish its structural properties, and demonstrate a biological role. Some proposed functional assemblies are dynamic or reversible and differ substantially from persistent pathological deposits. Nor is the functional–pathological boundary absolute: a useful assembly can become harmful if its regulation fails, and an aggregation-prone sequence may have both normal and disease-associated activities in different contexts."
    },
    {
      "heading": "Detection, molecular identification, and measurement",
      "text": "The classical tissue test combines Congo red staining with examination under polarized light. Binding of the dye to ordered fibrils produces characteristic optical behavior, making the method valuable for recognizing deposits in biopsies. Sensitivity depends on the amount and distribution of amyloid, tissue sampling, section preparation, and interpretation. A negative specimen from one anatomical site does not establish the absence of deposits everywhere else. Electron microscopy can reveal fine fibrils, but morphology generally cannot identify the precursor protein.\n\nTyping the deposit is a separate analytical task. Immunohistochemistry uses antibodies against candidate proteins, although performance depends on antibody specificity, tissue preservation, and the accessibility of epitopes within the deposited material. Laser microdissection followed by mass spectrometry can identify proteins in selected deposits and is widely used in specialist diagnostic laboratories. Interpretation considers the overall protein profile rather than treating the mere detection of one abundant circulating protein as decisive. Genetic analysis can establish a hereditary precursor variant, but a variant alone does not prove the composition of every deposit.\n\nIn research, thioflavin T fluorescence is commonly used to follow fibril formation. Its fluorescence increases strongly when binding restricts the dye’s molecular motion in suitable fibrillar environments. The assay is sensitive and convenient, but signal intensity depends on fibril structure, dye accessibility, and experimental conditions. Compounds being tested as aggregation inhibitors may alter fluorescence directly, absorb excitation light, or compete for binding. A reduced signal therefore requires confirmation by independent methods before it is interpreted as reduced fibril formation.\n\nStructural methods answer different questions. X-ray diffraction detects the characteristic cross-beta organization, while atomic-force and electron microscopy reveal dimensions and morphology. Solid-state nuclear magnetic resonance provides information about molecular conformation and intermolecular contacts. Cryo-electron microscopy can resolve ordered fibril cores at near-atomic resolution. No single method completely describes a heterogeneous sample containing monomers, oligomers, fibrils, associated lipids, and tissue-derived cofactors.\n\nClinical imaging and fluid measurements provide information unavailable from a small tissue section. Amyloid positron-emission tomography uses tracers that bind fibrillar amyloid-beta in the brain. Bone-avid radionuclide imaging has an established role in identifying cardiac ATTR under defined diagnostic conditions, including assessment for a monoclonal protein. Cerebrospinal-fluid and blood biomarkers can reflect amyloid-beta metabolism and associated tau changes, although they do not simply measure total deposited mass. Seed-amplification assays, including methods used in prion disease and alpha-synuclein research, detect templating activity; their results depend on assay conditions and should not be equated automatically with infectious dose or clinical severity."
    },
    {
      "heading": "Therapeutic strategies and their mechanistic basis",
      "text": "Interventions against amyloid-related disease act at several stages: reducing precursor production, stabilizing a native protein, changing aggregate formation, promoting removal, or treating downstream organ injury. The appropriate molecular target depends on the identified amyloid type. Similar-looking deposits do not imply interchangeable treatment, and a strategy effective for one precursor may have no effect on another. Clinical efficacy also depends on disease stage, tissue distribution, reversibility of injury, and treatment-associated risks.\n\nIn AL amyloidosis, treatment targets the abnormal clone producing the amyloidogenic immunoglobulin light chain. Regimens include plasma-cell-directed agents, and selected patients undergo high-dose therapy with autologous hematopoietic stem-cell transplantation. Daratumumab, which targets CD38, has become part of established combination treatment. Suppression of precursor production can occur before improvement in organ function because existing deposits and tissue injury resolve more slowly. In AA amyloidosis, control of the underlying inflammatory process reduces the sustained supply of serum amyloid A; the relevant treatment consequently depends on the inflammatory disease.\n\nATTR therapies illustrate two distinct molecular approaches. Tafamidis binds transthyretin and stabilizes its tetrameric structure, reducing the dissociation that precedes aggregation. Other agents lower transthyretin production through nucleic-acid-based mechanisms. Patisiran and vutrisiran use RNA interference, while inotersen is an antisense oligonucleotide. Their regulatory indications differ by product, jurisdiction, and disease manifestation. These approaches reduce the availability of aggregation-prone precursor but do not necessarily remove all pre-existing deposits or reverse established tissue damage.\n\nIn Alzheimer disease, antibodies directed against aggregated amyloid-beta have demonstrated that brain amyloid can be substantially reduced pharmacologically. Lecanemab received traditional United States approval in 2023, and donanemab was approved there in 2024 for treatment initiated in the early symptomatic stages studied in trials. Randomized studies found slowing of clinical decline on group-level measures, not restoration of lost cognitive function or elimination of disease progression. An important adverse effect is amyloid-related imaging abnormalities, including edema and hemorrhagic changes, which require specific clinical monitoring.\n\nDirect clearance of deposits, inhibition of nucleation, and disruption of harmful protein interactions remain active areas of investigation. Experimental compounds may fail despite reducing aggregation in a simplified assay because they do not reach the relevant tissue, bind the disease-associated fibril structure, or act on the biologically important species. Mobilizing aggregates could also have effects different from merely reducing their total mass. For this reason, biochemical evidence of target engagement, changes in imaging or fluid markers, and clinically meaningful outcomes are evaluated as separate levels of evidence."
    },
    {
      "heading": "Amyloid as a material and an unresolved physical-biological problem",
      "text": "Amyloid fibrils are attractive model materials because their repeated backbone interactions produce strong, high-aspect-ratio structures from comparatively simple molecular building blocks. Depending on sequence and preparation, fibrils can form gels, films, networks, and composite materials. Their surfaces can display functional chemical groups or bind other molecules. These properties have motivated research into scaffolds, filtration media, catalytic supports, sensing systems, and templates for inorganic deposition. Most such applications remain distinct from established clinical uses.\n\nExperimental materials can be prepared from designed peptides or from proteins not normally associated with human amyloid disease. Processing conditions may involve heat, acidity, or controlled proteolysis to expose assembly-prone segments. Mechanical behavior depends not only on the strength of individual fibrils but also on network density, cross-linking, hydration, and interactions with other components. A material’s bulk stiffness therefore cannot be inferred solely from the molecular order of its fibrils. Likewise, persistence in a laboratory assay does not establish environmental stability or biological safety.\n\nA central physical question is how strongly an amino-acid sequence specifies its amyloid fold. Sequence constrains the available interactions, but environmental conditions, molecular cofactors, and pre-existing seeds influence which structure emerges. Modern prediction of soluble protein structures does not automatically solve this problem: amyloid formation involves intermolecular packing, alternative conformations, and kinetic selection. Structures determined from tissue provide essential constraints, yet even a detailed endpoint structure does not reveal every step by which it formed.\n\nAnother unresolved issue is the relationship between liquid-like protein condensates and fibrillar assembly. Liquid–liquid phase separation can concentrate proteins into droplets, potentially changing nucleation rates and local chemical conditions. In some experimental systems, condensates mature into less dynamic aggregates or fibrillar networks. In others, condensation maintains proteins in a reversible state or sequesters aggregation-prone molecules. Condensates and amyloids are therefore not synonyms, and a universal progression from droplets to fibrils is not supported.\n\nThe biological significance of structural variation remains equally important. Different folds can expose different molecular surfaces, fragment at different rates, interact with different cellular receptors, or resist degradation to different degrees. Determining which of these properties actually explains disease patterns requires experiments that connect structure with behavior in cells, tissues, and organisms. Tissue-derived fibrils also contain or associate with non-protein components whose roles may range from incidental trapping to essential stabilization. Resolving these relationships requires methods that preserve molecular context while distinguishing the ordered fibril core from the surrounding biological material."
    }
  ],
  "links": [
    "protein",
    "protein-folding",
    "starch",
    "hydrogen-bond",
    "hydrophobic-effect",
    "cryo-electron-microscopy",
    "ph",
    "temperature",
    "mutation",
    "autophagy",
    "plasma-cell",
    "inflammation",
    "alzheimers-disease",
    "synapse",
    "prion",
    "bacteria",
    "biofilm",
    "dna",
    "immunohistochemistry",
    "mass-spectrometry",
    "nuclear-magnetic-resonance",
    "positron-emission-tomography",
    "biomarker"
  ],
  "sources": [],
  "license": "https://creativecommons.org/licenses/by/4.0/"
}